MedPath

A Clinical Study of Hyperthyroidism in Children

Recruiting
Conditions
Hyperthyroidism
Registration Number
NCT06570967
Lead Sponsor
Shengjing Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Inclusion Criteria:<br><br> 1. Age =14 years old<br><br> 2. Initial diagnosis of hyperthyroidism<br><br>Exclusion Criteria:<br><br> 1. Hyperthyroidism had been treated with medication in other hospitals,<br><br> 2. History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone<br> marrow or liver transplantation,<br><br> 3. Patients with incomplete clinical data

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational [Patient Registry]
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Remission of hyperthyroidism in children treated with methimazole. Remission is defined as having clinical and biochemical euthyroidism(FT3, FT4 and TSH are normal) without methimazole treatment for at least 12 months.;Adverse effects of methimazole in the treatment of hyperthyroidism in children. Adverse effects are defined as having neutropenia (absolute neutrophil count< 1500/µL), liver dysfunction (AST or ALT> 60 IU/L), rash, arthralgia, myalgia, et al.
Secondary Outcome Measures
NameTimeMethod
Relapse of hyperthyroidism in children treated with methimazole. Relapse was defined as having clinical and biochemical hyperthyroidism (FT3 and FT4 increased and TSH decreased) after discontinuation of methimazole.
© Copyright 2025. All Rights Reserved by MedPath